We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Preclinical models of pancreatic ductal adenocarcinoma.
Chinese Clinical Oncology 2017 June
Unlike many other cancers, pancreatic ductal adenocarcinoma (PDAC) has seen only incremental improvement in mortality despite significant advances in our understanding of the underlying biology. A primary obstacle to progress has been our inability to properly model PDAC in a preclinical setting. PDAC is difficult to study because of its genetic heterogeneity, intricate stromal microenvironment, and complex interplay with our immune system. Finding a model that properly accounts for all these criteria remains difficult. This review summarizes the five primary models currently in use: human PDAC cell line, cell line xenograft, patient derived xenograft, genetically engineered mouse model (GEMM), and organoids. We delve into the advantages of disadvantages of each model, while discussing how each model has been or could be used in the preclinical setting.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app